Every SEC Form 3/4/5 on record for this filer (CIK 1562645) — 8 issuers, 36 transactions. Section-16 filings only: what they filed, not a biography, and titles are as filed on their latest form at each issuer.
| Ticker | Company | Role as filed | On file | Forms | Open-market net |
|---|---|---|---|---|---|
| AMRX | Amneal Pharmaceuticals, Inc. | Director | 2019-12-16 → 2026-05-08 | 11 | — |
| PM | Philip Morris International Inc. | Director | 2021-05-07 → 2026-05-08 | 7 | — |
| GRA | W R GRACE & CO | Director · lapsed | 2018-05-11 → 2021-09-22 | 6 | — |
| CBM | CAMBREX CORP | Director · lapsed | 2016-04-22 → 2019-12-05 | 5 | −$2M |
| PDLI | PDL BIOPHARMA, INC. | Director · lapsed | 2018-06-12 → 2019-06-24 | 3 | — |
| XELA | Exela Technologies, Inc. | Director · lapsed | 2017-07-14 → 2017-07-14 | 1 | — |
| SGNT | Sagent Pharmaceuticals, Inc. | Director · lapsed | 2016-02-23 → 2016-08-31 | 3 | — |
| PRGO | PERRIGO Co plc | Director · lapsed | 2015-11-06 → 2016-05-23 | 4 | — |
No open-market buy or sale on record — only grants, exercises, withholding or gifts. Switch to “All forms” to see them.
3 of 8 issuers are covered and open a security page; the rest are on file here only.
